The pharmacological role of P-glycoprotein in the intestinal epithelium

Pharmacological Research

Volumn 37, Issue 6, 1998, Pages 429-435

  Van Asperen, Judith ^a   Van Tellingen, Olaf ^a   Beijnen, Jos H ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Intestinal secretion; Intestine; Oral bioavailability; P glycoprotein; Reversal agents

Indexed keywords

CARRIER PROTEIN; CYCLOSPORIN A; GLYCOPROTEIN P;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; INTESTINE EPITHELIUM; PRIORITY JOURNAL; REVIEW;

EID: 0032101275     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0326     Document Type: Article

References (40)

1. 1. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997; 25: 129-57.
2. 2. Kararli TT. Gastrointestinal absorption of drugs. Crit Rev Ther Drug Carrier Syst 1989; 6: 39-86.
3. 3. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996; 13: 963-77.
4. 4. Gan L-SL, Thakker DR. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 1997; 23: 77-98.
5. 5. Aungst BJ. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 1993; 82: 979-87.
6. 6. Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Wyvill KM, Flora KP, Broder S, Johns DG. Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther 1991; 50: 278-85.
7. 7. Dayton PG, Israili ZH, Henderson JD. Elimination of drugs by passive diffusion from blood to intestinal lumen: factors influencing nonbiliary excretion by the intestinal tract. Drug Metab Rev 1983; 14: 1193-206.
8. 8. Israili ZH, Dayton PG. Enhancement of xenobiotic elimination: role of intestinal excretion. Drug Metab Rev 1984; 15: 1123-59.
9. 9. George CF, Gruchy BS. Elimination of drugs by active intestinal transport. J Pharm Pharmacol 1979; 31: 643-4.
10. 10. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
11. 11. Shore PA, Brodie BB, Hogben CAM. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957; 119: 361-9.
12. 12. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
13. 13. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
14. 14. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
15. 15. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, van Asperen J, Borst P, Schinkel AH. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. Br J Pharmacol 1996; 119: 1038-44.
16. 16. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430-6.
17. 17. Su S-F, Huang J-D. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996; 24: 142-7.
18. 18. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 1996; 48: 1083-9.
19. 19. Kelly RA, Smith TW. Pharmacological treatment of heart failure. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. The pharmacological basis of therapeutics. USA: McGraw-Hill, 1996: 809-38.
20. 20. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-94.
21. 21. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-5.
22. 22. Van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Nooijen WJ, Beijnen JH. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blockers SDZ PSC 833 or cyclosporin A. Proc Am Assoc Cancer Res 1997; 38: 5 (abstr.).
23. 23. Van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997; 76: 1181-3.
24. 24. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992; 51: 433-8.
25. 25. Leu B-L, Huang J-D. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995; 35: 432-6.
26. 26. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporinemetabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5.
27. 27. Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-34.
28. 28. Tamai I, Saheki A, Saitoh R, Sai Y, Yamada I, Tsuji A. Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters. J Pharmacol Exp Ther 1997; 283: 108-15.
29. 29. Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R. Absorption of ofloxacin isomers in the rat small intestine. Antimicrob Agents Chemother 1997; 41: 2274-7.
30. 30. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-19.
31. 31. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-9.
32. 32. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro - in vivo correlation. Br J Pharmacol 1996; 118: 1841-7.
33. 33. Lown KS, Mayo RR, Leichtman AB, Hsiao H-L, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-60.
34. 34. Pedersen KE, Thayssen P, Klitgaard NA, Christiansen BD, Nielsen-Kudsk F. Influence of verapamil on the inotropism and pharmacokinetics of digoxin. Eur J Clin Pharmacol 1983; 25: 199-206.
35. 35. Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995; 13: 2039-42.
36. 36. Fedeli L, Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, Del Fevero A, Rossetti R, Tonato M, Rambotti P, Davis S. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 1989; 64: 1805-11.
37. 37. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42.
38. 38. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-18.
39. 39. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, van Tellingen O, Swart M, Schellens JHM. Cyclosporin A strongly enhances oral bioavailability of paclitaxel in cancer patients. Proc Am Assoc Clin Oncol 1998; in press (abstr.).
40. 40. Van Asperen J, Mayer U, van Tellingen O, Beijnen JH. The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 1997; 86: 881-4.